SEARCH

SEARCH BY CITATION

References

  • 1
    Hofmann O, Caballero OL, Stevenson BJ, Chen YT, Cohen T, Chua R, et al. Genome-wide analysis of cancer/testis gene expression. Proc Natl Acad Sci U S A 2008;105:20422-20427.
  • 2
    Old LJ. Cancer/testis (CT) antigens — a new link between gametogenesis and cancer. Cancer Immun 2001;1:1.
  • 3
    Scanlan MJ, Simpson AJ, Old LJ. The cancer/testis genes: review, standardization, and commentary. Cancer Immun 2004;4:1.
  • 4
    Simpson AJ, Caballero OL, Jungbluth A, Chen YT, Old LJ. Cancer/testis antigens, gametogenesis and cancer. Nat Rev Cancer 2005;5:615-625.
  • 5
    Stevenson BJ, Iseli C, Panji S, Zahn-Zabal M, Hide W, Old LJ, et al. Rapid evolution of cancer/testis genes on the X chromosome. BMC Genomics 2007;8:129.
  • 6
    Ross MT, Grafham DV, Coffey AJ, Scherer S, McLay K, Muzny D, et al. The DNA sequence of the human X chromosome. Nature 2005;434:325-337.
  • 7
    Mellstedt H, Vansteenkiste J, Thatcher N. Vaccines for the treatment of non-small cell lung cancer: investigational approaches and clinical experience. Lung Cancer 2011;73:11-17.
  • 8
    Robbins PF, Morgan RA, Feldman SA, Yang JC, Sherry RM, Dudley ME, et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol 2011;29:917-924.
  • 9
    Han ZG. Functional genomic studies: insights into the pathogenesis of liver cancer. Annu Rev Genomics Hum Genet 2012;13:171-205.
  • 10
    Wu LQ, Lu Y, Wang XF, Lv ZH, Zhang B, Yang JY. Expression of cancer-testis antigen (CTA) in tumor tissues and peripheral blood of Chinese patients with hepatocellular carcinoma. Life Sci 2006;79:744-748.
  • 11
    Zhao L, Mou DC, Leng XS, Peng JR, Wang WX, Huang L, et al. Expression of cancer-testis antigens in hepatocellular carcinoma. World J Gastroenterol 2004;10:2034-2038.
  • 12
    Bai J, Binari R, Ni JQ, Vijayakanthan M, Li HS, Perrimon N. RNA interference screening in Drosophila primary cells for genes involved in muscle assembly and maintenance. Development 2008;135:1439-1449.
  • 13
    Patterson KI, Brummer T, O'Brien PM, Daly RJ. Dual-specificity phosphatases: critical regulators with diverse cellular targets. Biochem J 2009;418:475-489.
  • 14
    Zhang ZY. Protein tyrosine phosphatases: structure and function, substrate specificity, and inhibitor development. Annu Rev Pharmacol Toxicol 2002;42:209-234.
  • 15
    Almeida LG, Sakabe NJ, deOliveira AR, Silva MC, Mundstein AS, Cohen T, et al. CTdatabase: a knowledge-base of high-throughput and curated data on cancer-testis antigens. Nucleic Acids Res 2009;37:D816-819.
  • 16
    Jongeneel CV, Delorenzi M, Iseli C, Zhou D, Haudenschild CD, Khrebtukova I, et al. An atlas of human gene expression from massively parallel signature sequencing (MPSS). Genome Res 2005;15:1007-1014.
  • 17
    Boutros M, Bras LP, Huber W. Analysis of cell-based RNAi screens. Genome Biol 2006;7:R66.
  • 18
    Chang BD, Broude EV, Dokmanovic M, Zhu H, Ruth A, Xuan Y, et al. A senescence-like phenotype distinguishes tumor cells that undergo terminal proliferation arrest after exposure to anticancer agents. Cancer Res 1999;59:3761-3767.
  • 19
    Wayne CM, MacLean JA, Cornwall G, Wilkinson MF. Two novel human X-linked homeobox genes, hPEPP1 and hPEPP2, selectively expressed in the testis. Gene 2002;301:1-11.
  • 20
    Heidebrecht HJ, Claviez A, Kruse ML, Pollmann M, Buck F, Harder S, et al. Characterization and expression of CT45 in Hodgkin's lymphoma. Clin Cancer Res 2006;12:4804-4811.
  • 21
    Chen YT, Scanlan MJ, Venditti CA, Chua R, Theiler G, Stevenson BJ, et al. Identification of cancer/testis-antigen genes by massively parallel signature sequencing. Proc Natl Acad Sci U S A 2005;102:7940-7945.
  • 22
    Hahn Y, Lee B. Identification of nine human-specific frameshift mutations by comparative analysis of the human and the chimpanzee genome sequences. Bioinformatics 2005;21(Suppl 1):i186-i194.
  • 23
    Hood KL, Tobin JF, Yoon C. Identification and characterization of two novel low-molecular-weight dual specificity phosphatases. Biochem Biophys Res Commun 2002;298:545-551.
  • 24
    Rardin MJ, Wiley SE, Murphy AN, Pagliarini DJ, Dixon JE. Dual specificity phosphatases 18 and 21 target to opposing sides of the mitochondrial inner membrane. J Biol Chem 2008;283:15440-15450.
  • 25
    Minakuchi Y, Takeshita F, Kosaka N, Sasaki H, Yamamoto Y, Kouno M, et al. Atelocollagen-mediated synthetic small interfering RNA delivery for effective gene silencing in vitro and in vivo. Nucleic Acids Res 2004;32:e109.
  • 26
    Takei Y, Takigahira M, Mihara K, Tarumi Y, Yanagihara K. The metastasis-associated microRNA miR-516a-3p is a novel therapeutic target for inhibiting peritoneal dissemination of human scirrhous gastric cancer. Cancer Res 2011;71:1442-1453.
  • 27
    Tian K, Yang S, Ren Q, Han Z, Lu S, Ma F, et al. p38 MAPK contributes to the growth inhibition of leukemic tumor cells mediated by human umbilical cord mesenchymal stem cells. Cell Physiol Biochem 2010;26:799-808.
  • 28
    Campbell JS, Argast GM, Yuen SY, Hayes B, Fausto N. Inactivation of p38 MAPK during liver regeneration. Int J Biochem Cell Biol 2011;43:180-188.
  • 29
    Kong S, Sengupta S, Tyler B, Bais AJ, Ma Q, Doucette S, et al. Suppression of Human Glioma Xenografts with Second-Generation IL13R-Specific Chimeric Antigen Receptor-Modified T Cells. Clin Cancer Res 2012;18:5949-5960.
  • 30
    Zhang Y, Li Q, Liu N, Song T, Liu Z, Guo R, et al. Detection of MAGE-1, MAGE-3 and AFP mRNA as multimarker by real-time quantitative PCR assay: a possible predictor of hematogenous micrometastasis of hepatocellular carcinoma. Hepatogastroenterology 2008;55:2200-2206.
  • 31
    Roch N, Kutup A, Vashist Y, Yekebas E, Kalinin V, Izbicki JR. Coexpression of MAGE-A peptides and HLA class I molecules in hepatocellular carcinoma. Anticancer Res 2010;30:1617-1623.
  • 32
    Andrade VC, Vettore AL, Regis Silva MR, Felix RS, Almeida MS, de Carvalho F, et al. Frequency and prognostic relevance of cancer testis antigen 45 expression in multiple myeloma. Exp Hematol 2009;37:446-449.
  • 33
    Chen YT, Ross DS, Chiu R, Zhou XK, Chen YY, Lee P, et al. Multiple cancer/testis antigens are preferentially expressed in hormone-receptor negative and high-grade breast cancers. PLoS One 2011;6:e17876.
  • 34
    Gonzales FA, Zanchin NI, Luz JS, Oliveira CC. Characterization of Saccharomyces cerevisiae Nop17p, a novel Nop58p-interacting protein that is involved in Pre-rRNA processing. J Mol Biol 2005;346:437-455.
  • 35
    Schuller M, Jenne D, Voltz R. The human PNMA family: novel neuronal proteins implicated in paraneoplastic neurological disease. J Neuroimmunol 2005;169:172-176.
  • 36
    Bakan A, Lazo JS, Wipf P, Brummond KM, Bahar I. Toward a molecular understanding of the interaction of dual specificity phosphatases with substrates: insights from structure-based modeling and high throughput screening. Curr Med Chem 2008;15:2536-2544.
  • 37
    Luo J, Solimini NL, Elledge SJ. Principles of cancer therapy: oncogene and non-oncogene addiction. Cell 2009;136:823-837.
  • 38
    Zama T, Aoki R, Kamimoto T, Inoue K, Ikeda Y, Hagiwara M. Scaffold role of a mitogen-activated protein kinase phosphatase, SKRP1, for the JNK signaling pathway. J Biol Chem 2002;277:23919-23926.